MicroPort® Awarded "Shanghai Top Brand"

Shanghai, China – Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®") was recently awarded "Shanghai Top Brand", according to a list released by Shanghai Top Brand Recommendation Committee, for its English and Chinese brand name "MicroPort®" and "微创®" (recommended product: Rapamycin-Eluting Coronary CoCr Stent System). MicroPort® has been awarded such honor for 12 consecutive years since 2005. The title will be valid till December 31, 2019.
Shanghai government started the selection of Shanghai Top Brands since 1994, aiming to cultivate a group of enterprises with independent intellectual properties and international competitiveness. Only companies with independent intellectual property, strong probability and competiveness are qualified to apply for the selection. The applicants will be strictly screened by government authorities including Shanghai Municipal Bureau of Quality and Technical Supervision, Shanghai Publicity Department, Shanghai Municipal Development and Reform Commission, and Shanghai State-owned Assets Supervision and Administration Committee, based on their social awareness, industry position, innovative ability, and etc. The applicants have to go through several rounds of review before they win the title of "Shanghai Top Brand".
Since its establishment in 1998, MicroPort® has been focusing on innovation. Currently, MicroPort® and its subsidiaries have a total of 1,900 issued patents, and were granted several national science and technology achievements awards and provincial-level honors. With over 200 products, covering 10 major medical disciplines including interventional cardiology, orthopedics, interventional radiology, electrophysiology, diabetes and endocrine management, surgical management, and others, currently approved for use in over 5,000 hospitals in major markets such as Asia Pacific, Europe and America, MicroPort® is contributing to a better world through its life-saving medical therapies and quality-improving care devices being used in patients every 15 seconds.
MicroPort® holds a leading position in China's drug eluting stent field since the launch of its drug-eluting stent in 2004, which is China's first domestically made drug-eluting stent. The recommended product of MicroPort® in "Shanghai Top Brand" selection, Rapamycin-Eluting Coronary CoCr Stent System, is the second-generation drug-eluting stent of MicroPort®, which excels in compliance, crossability, trackability, and postoperative immediate outcome. In particular, the launch of the world's first target-eluting stent in 2014 represented major leaps forward for MicroPort®, transforming its drug-eluting-stent offering from a market follower to a leader in this segment. Up to date, MicroPort® drug-eluting stents have entered Asia-Pacific, Europe, America and other major markets, and it is estimated that over three million coronary stents have been used to save the life of two million patients.
The title of "Shanghai Top Brand" signifies that the MicroPort® brand and its products are gaining higher social awareness, due to its industry-leading product quality and corporate governance. In the future, MicroPort® will continue to carry out the management credo of "Hands on Details, Eyes for Greatness" to offer cost-effective medical solutions to save or reshape lives or improve the quality of life for patients in China and worldwide.